MacroGenics, Inc. (NASDAQ:MGNX) Position Cut by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP decreased its stake in MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 18.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 717,288 shares of the biopharmaceutical company's stock after selling 165,372 shares during the period. Dimensional Fund Advisors LP owned approximately 1.14% of MacroGenics worth $2,331,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Barclays PLC lifted its stake in shares of MacroGenics by 97.1% in the third quarter. Barclays PLC now owns 98,753 shares of the biopharmaceutical company's stock worth $325,000 after acquiring an additional 48,639 shares in the last quarter. Sanders Morris Harris LLC acquired a new position in shares of MacroGenics in the fourth quarter worth about $40,000. XML Financial LLC lifted its stake in shares of MacroGenics by 31.6% in the fourth quarter. XML Financial LLC now owns 23,169 shares of the biopharmaceutical company's stock worth $75,000 after acquiring an additional 5,569 shares in the last quarter. SG Americas Securities LLC lifted its stake in shares of MacroGenics by 104.5% in the fourth quarter. SG Americas Securities LLC now owns 34,399 shares of the biopharmaceutical company's stock worth $112,000 after acquiring an additional 17,577 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of MacroGenics by 7.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 527,185 shares of the biopharmaceutical company's stock worth $1,713,000 after acquiring an additional 34,420 shares in the last quarter. Hedge funds and other institutional investors own 96.89% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. HC Wainwright cut their price target on MacroGenics from $4.00 to $2.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 25th. Barclays reiterated an "overweight" rating and issued a $3.00 price target (down previously from $8.00) on shares of MacroGenics in a research note on Wednesday. Stifel Nicolaus cut their price target on MacroGenics from $6.00 to $5.00 and set a "hold" rating on the stock in a research note on Wednesday. Finally, StockNews.com cut MacroGenics from a "buy" rating to a "hold" rating in a research note on Friday, March 21st. Eight analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, MacroGenics currently has an average rating of "Hold" and a consensus target price of $6.38.

MacroGenics Trading Up 2.6%

NASDAQ MGNX traded up $0.04 on Friday, hitting $1.58. 400,811 shares of the stock traded hands, compared to its average volume of 832,846. The stock has a 50-day moving average of $1.56 and a 200 day moving average of $2.61. MacroGenics, Inc. has a twelve month low of $0.99 and a twelve month high of $5.77. The company has a market capitalization of $99.68 million, a P/E ratio of -1.00 and a beta of 2.20.

MacroGenics (NASDAQ:MGNX - Get Free Report) last posted its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.04). The company had revenue of $13.19 million for the quarter, compared to the consensus estimate of $9.59 million. MacroGenics had a negative net margin of 69.07% and a negative return on equity of 89.42%. As a group, equities research analysts expect that MacroGenics, Inc. will post -1.06 earnings per share for the current year.

MacroGenics Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.